AMRI announced that it will be transitioning Discovery and Development Services (DDS) activities at its Syracuse, New York site to other sites within AMRI and will cease operations in Syracuse by the end of June 2014.

“The decision we have made, while difficult for our colleagues in Syracuse, reflects the continued evolution of AMRI's business to better align our operations to most efficiently support our customer needs, while preserving the skills and capabilities that our customers demand as they return to greater utilization of their outsourcing partners,” said William S. Marth, AMRI's president and chief executive officer, in a company release. “We remain committed to our total integrated discovery and development services platform and the capabilities for which Syracuse has become distinguished, and we will be transitioning and consolidating those activities to other sites within AMRI.”

AMRI's Syracuse Research Center provides services to the global pharmaceutical industry, including chemical process research and development, custom chemical synthesis, and scale-up of pharmaceutical intermediates and final products. As part of the transition, Syracuse DDS capabilities and some employees will be transferred to a number of AMRI facilities, including Albany, New York.; Cedarburg, Wisconsin; Holywell, United Kingdom; and Hyderabad, India. AMRI expects to finalize transition plans by the end of April 2014 and anticipates no interruption to current or future projects, which require Syracuse specific capabilities.

Source: AMRI